Pharmacy actuarial experts discuss the potential implications of the recent Rx Executive Order and Tariffs on various groups of stakeholders in the United States pharmacy eco-system.
{{ day.Date }}
{{ time.Time }}
{{ session.Description }}
{{ session.Description }}